Cargando…

Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency

SIMPLE SUMMARY: Many aspects of the regulatory mechanisms of somatic cell reprogramming—the conversion of any cell type into pluripotent stem cells—still remain elusive. The tumor suppressor CYLD regulates several signaling pathways involved in this process. However, its potential role in reprogramm...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekas, Nikolaos, Samiotaki, Martina, Papathanasiou, Maria, Mokos, Panagiotis, Pseftogas, Athanasios, Xanthopoulos, Konstantinos, Thanos, Dimitris, Mosialos, George, Dafou, Dimitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605754/
https://www.ncbi.nlm.nih.gov/pubmed/37894364
http://dx.doi.org/10.3390/cancers15204997
_version_ 1785127153988272128
author Bekas, Nikolaos
Samiotaki, Martina
Papathanasiou, Maria
Mokos, Panagiotis
Pseftogas, Athanasios
Xanthopoulos, Konstantinos
Thanos, Dimitris
Mosialos, George
Dafou, Dimitra
author_facet Bekas, Nikolaos
Samiotaki, Martina
Papathanasiou, Maria
Mokos, Panagiotis
Pseftogas, Athanasios
Xanthopoulos, Konstantinos
Thanos, Dimitris
Mosialos, George
Dafou, Dimitra
author_sort Bekas, Nikolaos
collection PubMed
description SIMPLE SUMMARY: Many aspects of the regulatory mechanisms of somatic cell reprogramming—the conversion of any cell type into pluripotent stem cells—still remain elusive. The tumor suppressor CYLD regulates several signaling pathways involved in this process. However, its potential role in reprogramming has not been investigated. In this work, we present evidence that CYLD exerts important regulatory control at the early stages of reprogramming. Loss of CYLD catalytic activity leads to the reduced reprogramming efficiency of mouse embryonic fibroblasts. Whole proteome analysis during early reprogramming stages revealed that CYLD DUB deficiency impedes a vital early reprogramming step known as the mesenchymal-to-epithelial transition (MET). Our findings expand our knowledge of early reprogramming mechanics and reveal a novel role for CYLD as an extracellular matrix regulator. ABSTRACT: CYLD is a tumor suppressor gene coding for a deubiquitinating enzyme that has a critical regulatory function in a variety of signaling pathways and biological processes involved in cancer development and progression, many of which are also key modulators of somatic cell reprogramming. Nevertheless, the potential role of CYLD in this process has not been studied. With the dual aim of investigating the involvement of CYLD in reprogramming and developing a better understanding of the intricate regulatory system governing this process, we reprogrammed control (CYLD(WT/WT)) and CYLD DUB-deficient (CYLD(Δ9/Δ9)) mouse embryonic fibroblasts (MEFs) into induced pluripotent stem cells (iPSCs) through ectopic overexpression of the Yamanaka factors (Oct3/4, Sox2, Klf4, c-myc). CYLD DUB deficiency led to significantly reduced reprogramming efficiency and slower early reprogramming kinetics. The introduction of WT CYLD to CYLD(Δ9/Δ9) MEFs rescued the phenotype. Nevertheless, CYLD DUB-deficient cells were capable of establishing induced pluripotent colonies with full spontaneous differentiation potential of the three germ layers. Whole proteome analysis (Data are available via ProteomeXchange with identifier PXD044220) revealed that the mesenchymal-to-epithelial transition (MET) during the early reprogramming stages was disrupted in CYLD(Δ9/Δ9) MEFs. Interestingly, differentially enriched pathways revealed that the primary processes affected by CYLD DUB deficiency were associated with the organization of the extracellular matrix and several metabolic pathways. Our findings not only establish for the first time CYLD’s significance as a regulatory component of early reprogramming but also highlight its role as an extracellular matrix regulator, which has profound implications in cancer research.
format Online
Article
Text
id pubmed-10605754
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106057542023-10-28 Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency Bekas, Nikolaos Samiotaki, Martina Papathanasiou, Maria Mokos, Panagiotis Pseftogas, Athanasios Xanthopoulos, Konstantinos Thanos, Dimitris Mosialos, George Dafou, Dimitra Cancers (Basel) Article SIMPLE SUMMARY: Many aspects of the regulatory mechanisms of somatic cell reprogramming—the conversion of any cell type into pluripotent stem cells—still remain elusive. The tumor suppressor CYLD regulates several signaling pathways involved in this process. However, its potential role in reprogramming has not been investigated. In this work, we present evidence that CYLD exerts important regulatory control at the early stages of reprogramming. Loss of CYLD catalytic activity leads to the reduced reprogramming efficiency of mouse embryonic fibroblasts. Whole proteome analysis during early reprogramming stages revealed that CYLD DUB deficiency impedes a vital early reprogramming step known as the mesenchymal-to-epithelial transition (MET). Our findings expand our knowledge of early reprogramming mechanics and reveal a novel role for CYLD as an extracellular matrix regulator. ABSTRACT: CYLD is a tumor suppressor gene coding for a deubiquitinating enzyme that has a critical regulatory function in a variety of signaling pathways and biological processes involved in cancer development and progression, many of which are also key modulators of somatic cell reprogramming. Nevertheless, the potential role of CYLD in this process has not been studied. With the dual aim of investigating the involvement of CYLD in reprogramming and developing a better understanding of the intricate regulatory system governing this process, we reprogrammed control (CYLD(WT/WT)) and CYLD DUB-deficient (CYLD(Δ9/Δ9)) mouse embryonic fibroblasts (MEFs) into induced pluripotent stem cells (iPSCs) through ectopic overexpression of the Yamanaka factors (Oct3/4, Sox2, Klf4, c-myc). CYLD DUB deficiency led to significantly reduced reprogramming efficiency and slower early reprogramming kinetics. The introduction of WT CYLD to CYLD(Δ9/Δ9) MEFs rescued the phenotype. Nevertheless, CYLD DUB-deficient cells were capable of establishing induced pluripotent colonies with full spontaneous differentiation potential of the three germ layers. Whole proteome analysis (Data are available via ProteomeXchange with identifier PXD044220) revealed that the mesenchymal-to-epithelial transition (MET) during the early reprogramming stages was disrupted in CYLD(Δ9/Δ9) MEFs. Interestingly, differentially enriched pathways revealed that the primary processes affected by CYLD DUB deficiency were associated with the organization of the extracellular matrix and several metabolic pathways. Our findings not only establish for the first time CYLD’s significance as a regulatory component of early reprogramming but also highlight its role as an extracellular matrix regulator, which has profound implications in cancer research. MDPI 2023-10-15 /pmc/articles/PMC10605754/ /pubmed/37894364 http://dx.doi.org/10.3390/cancers15204997 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bekas, Nikolaos
Samiotaki, Martina
Papathanasiou, Maria
Mokos, Panagiotis
Pseftogas, Athanasios
Xanthopoulos, Konstantinos
Thanos, Dimitris
Mosialos, George
Dafou, Dimitra
Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency
title Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency
title_full Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency
title_fullStr Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency
title_full_unstemmed Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency
title_short Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency
title_sort inactivation of tumor suppressor cyld inhibits fibroblast reprogramming to pluripotency
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605754/
https://www.ncbi.nlm.nih.gov/pubmed/37894364
http://dx.doi.org/10.3390/cancers15204997
work_keys_str_mv AT bekasnikolaos inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency
AT samiotakimartina inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency
AT papathanasioumaria inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency
AT mokospanagiotis inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency
AT pseftogasathanasios inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency
AT xanthopouloskonstantinos inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency
AT thanosdimitris inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency
AT mosialosgeorge inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency
AT dafoudimitra inactivationoftumorsuppressorcyldinhibitsfibroblastreprogrammingtopluripotency